WASF2 and neoplasm: We analyzed WASF2 promoter methylation levels in paired human HCC tissues using qMSP; 60 and 56% of the tumor tissues in the test (n = 20) and validation (n = 18) cohorts, respectively, were hypomethylated compared to non-tumor tissues (Fig. 5E, F).